Ask AI



Table of contents

Juvenile idiopathic arthritis-associated uveitis


Key sources

The following summarized guidelines for the evaluation and management of juvenile idiopathic arthritis-associated uveitis are prepared by our editorial team based on guidelines from the Arthritis Foundation (AF/ACR 2019), the German Society of Pediatric Rheumatology (GKJR/BVA/DGRh/DOG 2019), and the Single Hub and Access Point for Pediatric Rheumatology in Europe (SHARE initiative 2018). ...
Show more

Screening and diagnosis

Indications for screening: as per ACR/AF 2019 guidelines, consider obtaining ophthalmic screening every 3 months in pediatric and adolescent patients with JIA at high risk of developing uveitis.
Create free account

Classification and risk stratification

Severity assessment: as per SHARE initiative 2018 guidelines, insufficient evidence to recommend a validated biomarker to follow the activity of uveitis.

Medical management

General principles: as per BVA/DGRh/DOG/GKJR 2019 guidelines, initiate treatment in patients with JIA-associated active uveitis.

More topics in this section

  • Topical corticosteroids

  • DMARDs (conventional DMARDs)

  • DMARDs (biological DMARDs)

  • Systemic corticosteroids

  • NSAIDs

  • Cycloplegics

Therapeutic procedures

Ocular corticosteroid injections: as per BVA/DGRh/DOG/GKJR 2019 guidelines, consider administering ocular corticosteroid injections as rescue therapy in individual patients with unilateral or bilateral severe active uveitis with prognostic risk factors for impending uveitis-related deterioration of vision (such as hypotony, macular edema, or dense vitreous opacities), after exhaustion of all other treatment options.

Patient education

General counseling: as per ACR/AF 2019 guidelines, educate pediatric and adolescent patients with spondyloarthritis regarding the warning signs of acute anterior uveitis for the purpose of decreasing the delay in treatment, duration of symptoms, or complications of iritis.

Follow-up and surveillance

Assessment of treatment response: as per ACR/AF 2019 guidelines, obtain ophthalmic monitoring within 1 month after each change of topical corticosteroids in patients with controlled uveitis tapering or discontinuing topical corticosteroids.
Show 2 more

More topics in this section

  • Treatment tapering